Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions
MONDO:0006397A group of kidney carcinomas characterized by the presence of different translocations involving the chromosome Xp11.2. These translocations result in the creation of gene fusions involving the TFE3 gene. Patients are usually children and young adults. Morphologically, the malignant epithelial cells form papillary patterns.
Also known as: TFE3-Rearranged renal cell carcinoma, Xp11.2 translocation-related renal cell carcinoma, renal cell cancer associated with Xp11.2 translocations/TFE3 Gene fusions, renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions, tRCC, translocation-associated renal cell carcinoma
2783 clinical trials for this condition and its sub-types, 7 tagged with Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Head-to-Head drug battle for rare kidney cancer
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New combo shows promise for rare kidney cancers
Disease control OngoingThis study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …
Phase 1/2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC